---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-063938"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T12:45:55.852223+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# IDEAYA Q1 2025 net loss $72.2M; cash ~$1.05B funds ops into 2029; darovasertib enrollment >300 pts

## Summary
- Cash, equivalents and securities $1.05B as of March 31, 2025, supporting updated runway into 2029.
- Net loss of $72.2M in Q1 2025; R&D expenses $70.9M (down from $140.2M Q4 2024 incl. one-time $75M license payment).
- Over 300 patients enrolled in darovasertib + crizotinib 1L MUM registrational trial; median PFS readout targeted by YE 2025.
- FDA Breakthrough Therapy designation for neoadjuvant darovasertib in primary UM; Phase 3 design finalized after Type D meeting.
- Three IND filings targeted in 2025: PRMT5 (IDE892), B7H3/PTK7 ADC (IDE034), KAT6/7 (IDE574); IDE849 Phase 1 started in US.

## SEC filing metadata
- accession: 0000950170-25-063938
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000095017025063938/0000950170-25-063938-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000095017025063938/idya-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-063938
- JSON: https://secwatch.observer/filing/0000950170-25-063938.json
- Plain text: https://secwatch.observer/filing/0000950170-25-063938.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.